190 related articles for article (PubMed ID: 30309697)
21. Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?
Soška V; Kyselák O
Vnitr Lek; 2021; 67(3):138-142. PubMed ID: 34171952
[TBL] [Abstract][Full Text] [Related]
22. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
23. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
24. Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting.
Scicali R; Di Pino A; Ferrara V; Rabuazzo AM; Purrello F; Piro S
Acta Diabetol; 2021 Jul; 58(7):949-957. PubMed ID: 33745063
[TBL] [Abstract][Full Text] [Related]
25. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
26. [Antibodies in addition to statin therapy lowers LDL cholesterol].
Bossenmayer S
Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
[No Abstract] [Full Text] [Related]
27. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
28. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
[TBL] [Abstract][Full Text] [Related]
29. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
30. [Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets].
Masana L; Plana N
Clin Investig Arterioscler; 2015; 27(3):138-43. PubMed ID: 25865752
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
[TBL] [Abstract][Full Text] [Related]
32. Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Krähenbühl S; Pavik-Mezzour I; von Eckardstein A
Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066
[TBL] [Abstract][Full Text] [Related]
33. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
35. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
36. Management of patients with statin intolerance.
Fischer S; Julius U
Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake.
Lupo MG; Macchi C; Marchianò S; Cristofani R; Greco MF; Dall'Acqua S; Chen H; Sirtori CR; Corsini A; Ruscica M; Ferri N
Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1245-1253. PubMed ID: 31439394
[TBL] [Abstract][Full Text] [Related]
39. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
40. PCSK9 inhibitors: A new improvement for health.
Perelló Camacho E
Clin Investig Arterioscler; 2019; 31(5):241-243. PubMed ID: 30737073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
